Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Recipient : Rhythm Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Genpharm will distribute Imcivree (setmelanotide) to patients in GCC countries for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, PCSK1, or leptin recept...
Product Name : Imcivree
Product Type : Peptide
Upfront Cash : Undisclosed
May 22, 2023
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Recipient : Rhythm Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Genpharm Services has exclusive rights to commercialize QRX003 in the Middle East and North Africa region, upon the receipt of regulatory approvals in both territories.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 11, 2021
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Recipient : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement with Genpharm advances Albireo’s global strategy for the commercialization of Bylvay in a key region following European and U.S. regulatory approvals of the use of Bylvay in patients with PFIC based on the PEDFIC study.
Product Name : Bylvay
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Recipient : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Atidarsagene Autotemcel
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under terms of the agreements, GenPharm and GEN will be responsible for all activities related to identifying patients, driving disease awareness, and ensuring market access for Libmeldy in their respective territories.
Product Name : Libmeldy
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Atidarsagene Autotemcel
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rimegepant Sulfate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Biohaven Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East
Details : Biohaven and Genpharm's agreement will bring NURTEC™ ODT, the first oral, quick-dissolve, calcitonin gene related peptide antagonist to patients in the Middle East and the Gulf Region.
Product Name : Nurtec ODT
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2020
Lead Product(s) : Rimegepant Sulfate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Biohaven Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement